Schizophrenia is an all-too-often chronic, debilitating disorder that impedes quality of life and psychosocial functioning. Implementation of effective therapy that promotes sustained recovery often poses a challenge for both clinicians and patients. Long-acting injectables (LAIs) can play a critical role in relapse prevention and rehospitalization, and subsequently, recovery and restoration of function.
This CME Outfitters BriefCase will guide clinicians through best practices to identify patients with schizophrenia who are ideal candidates for LAIs as well as effective communication strategies to facilitate the discussion of using LAIs in these patients.
At the end of this CME/CE activity, participants should be able to identify patients with schizophrenia who are ideal candidates for LAI therapies and strategies for transitioning from oral therapies.
The following learning objectives pertain only to those requesting CNE or CPE credit: Identify patients with schizophrenia who are ideal candidates for LAI therapies and strategies for transitioning from oral therapies.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc., and Lundbeck.
Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kane reports that he receives grants from Janssen Pharmaceuticals, Inc.; Lundbeck; and Otsuka America Pharmaceutical, Inc. He is a consultant for ACADIA Pharmaceuticals Inc.; Alkermes; Allergan; F. Hoffmann-La Roche; Intra-Cellular Therapies, Inc.; Lundbeck; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Johnson & Johnson; LB Pharmaceuticals, Inc.; Merck & Co., Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Reviva Pharmaceuticals Inc.; Saladax Biomedical, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva. He is a stock shareholder of Vanguard Research Group; and LB Pharmaceuticals, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).